Lipid‐modifying statins, fibrates reduce mortality in schizophrenia patients.

A nationwide cohort study conducted in Taiwan has found that lipid‐modifying agents, particularly statins and fibrates, reduce mortality risk in patients with schizophrenia. The reduced risk was apparent for both all‐cause and natural‐cause mortality, the investigators reported. Study results were published online May 16, 2024, in The British Journal of Psychiatry. [ABSTRACT FROM AUTHOR]